Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioSphere requests US trial for fibroid treatment:

This article was originally published in Clinica

Executive Summary

BioSphere Medical has filed an investigational device exemption application with the FDA to begin US trials of its microsphere embolisation technology as a treatment for uterine fibroids. The Embosphere microspheres, which has shown potential for uterine artery embolisation in animal studies, could provide a less invasive alternative to surgery for women with the condition, said the Marlborough, Massachusetts-based company. The product is already CE-marked in Europe and has been submitted to the FDA for treating hypervascularised tumours and arteriovenous malformations.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT079829

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel